These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32063109)

  • 1. Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
    Bondad N; Boostani R; Barri A; Elyasi S; Allahyari A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1575-1582. PubMed ID: 32063109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
    Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
    Yildirim N; Cengiz M
    Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer.
    Zhang X; Chen H; Lu Y; Xu C; Yao W; Xu L; Zhang R; Zhang L; Yao Q
    Medicine (Baltimore); 2020 Dec; 99(50):e23564. PubMed ID: 33327312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
    Thomas A; Virdee PS; Eatock M; Lord SR; Falk S; Anthoney DA; Turkington RC; Goff M; Elhussein L; Collins L; Love S; Moschandreas J; Middleton MR
    Eur J Cancer; 2020 Jan; 124():131-141. PubMed ID: 31765988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
    Cascinu S; Catalano V; Cordella L; Labianca R; Giordani P; Baldelli AM; Beretta GD; Ubiali E; Catalano G
    J Clin Oncol; 2002 Aug; 20(16):3478-83. PubMed ID: 12177109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of analgecine on oxaliplatin-induced neurotoxicity in patients with gastrointestinal cancer.
    Liu MY; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(10):4465-8. PubMed ID: 26028115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
    Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
    Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
    Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
    Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.
    Lin PC; Lee MY; Wang WS; Yen CC; Chao TC; Hsiao LT; Yang MH; Chen PM; Lin KP; Chiou TJ
    Support Care Cancer; 2006 May; 14(5):484-7. PubMed ID: 16450089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2).
    Motoo Y; Tomita Y; Fujita H
    Int J Clin Oncol; 2020 Jun; 25(6):1123-1129. PubMed ID: 32232692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
    Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
    Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity.
    Gui Q; Li D; Zhuge Y; Xu C
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):705-709. PubMed ID: 33773532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
    Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
    Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
    Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.